punicalin

Punicalin: A Comprehensive Reference Article

1. Identity: Chemical and Botanical Overview

1.1 Chemical Identity

Punicalin is a large polyphenol with the chemical formula C₃₄H₂₂O₂₂ and a molecular weight of approximately 782.5 g/mol. Its structure is characterized by a gallagic acid component linked to a glucose molecule, specifically identified as 4,6-(S,S)-gallagyl-D-glucose. Punicalin belongs to the class of compounds known as ellagitannins — hydrolyzable tannins that release ellagic acid upon hydrolysis. Punicalagin, a large polyphenol with a molecular weight greater than 1000, is unique to pomegranate and is part of a family of ellagitannins that includes the minor tannins punicalin and gallagic acid.

Punicalin's CAS registry number is 65995-64-4. Its chemical family is phenols and polyphenols, with confirmed botanical source in Punica granatum L. Punicalin (PNC) is described as one major ellagitannin (ET) in pomegranate peel.

1.2 Botanical Sources

The main source is the aril, husk, fruit, juice, and peel of pomegranate (Punica granatum). Punicalin co-occurs in the fruit alongside punicalagin, the more abundant and structurally larger ellagitannin of which punicalin can be considered a structural subunit or hydrolysis product. Ellagitannins in pomegranate fruit husk and juice include punicalin, punicalagin, corilagin, casuarinin, terminalin/gallagyldilacton, pedunculagin, tellimagrandin, granatin A, and granatin B.

Beyond pomegranate, punicalin has a broader plant distribution. Both punicalagin and punicalin have been identified in several Terminalia species, including T. catappa, T. chebula Retz, T. myriocarpa, and T. citrina. Punicalagin and punicalin, isolated from the leaves of Terminalia catappa L., are used to treat dermatitis and hepatitis. Additionally, pomegranate (Punica granatum L., Lythraceae) peel possesses several classes of phytochemicals, including hydrolyzable tannins, phenolic acids, triterpenoids, phytosterols, lignans, and flavonoids.

1.3 Common Forms and Preparations

Highest concentrations are found in the peel or husk of the fruit, though punicalin is also present in the white membranes surrounding the arils and, to a lesser extent, in the aril juice. For scientific and commercial purposes, pomegranate peels are dried and ground into a fine powder, after which the powdered peel is extracted with a suitable solvent, often an aqueous ethanol mixture (e.g., 80% methanol or ethanol).

Among various extraction techniques, high-speed homogenization yields the greatest quantity, followed by ultrasonic-assisted extraction, microwave-assisted extraction, Soxhlet, and enzyme-assisted extraction. Ultrasonic-assisted extraction (UAE) was further optimized using response surface methodology (RSM), and ellagitannin yield was maximized to 3.04% in terms of punicalin equivalent yield for UAE using RSM, significantly higher than conventional Soxhlet extraction (1.71%). LC-HRMS analysis found that Punicalin A and B were the major ellagitannins present in purified extracts apart from the hexose sugar of ellagic acid.

Punicalin is available as an isolated reference standard with HPLC purity exceeding 98% for research applications. As a dietary ingredient, it is most commonly encountered as a component of standardized pomegranate peel extracts rather than as an isolated compound supplement. The concentration of punicalagins and related ellagitannins in pomegranate peel can range from approximately 10 to 50 milligrams per gram.

2. Traditional and Historical Use

2.1 Geographic and Cultural Origins

Pomegranate (Punica granatum L.), belonging to the Lythraceae family, is a historic fruit indigenous to Central Asia and found in the Middle East, Iran, Turkmenistan, and northern India. The first record of pomegranate cultivation appears in 2200 B.C. near the Tigris and Euphrates Valleys in what is now Basra, Iraq.

Pomegranate (Punica granatum L.) has been used in traditional medicine in China and several regions of the world, including Ayurveda, Islamic, and Persian traditions, for the treatment of atherosclerosis, diabetes, hypertension, hyperlipidemia, and several types of cancer, as well as peptic ulcer and oral diseases for hundreds of years. References to the pomegranate are found in Christian, Islamic, and Jewish religious manuscripts, and in ancient Hindu and Chinese medicine systems.

2.2 Traditional Medical Systems

Pomegranate (Punica granatum L.), a member of the family Punicaceae, has a longstanding history of cultivation in China. The first documented medicinal use of various pomegranate parts, including the peel, seeds, flowers, leaves, and roots, dates back to the Han Dynasty, as recorded in Min-Yi-Bie-Lu (名医别录). Therefore, pomegranate has a very long history of use not only in traditional Chinese medicine but also in diverse clinical practices among Tibetans, Uyghurs, Miaos, and other ethnic groups.

Based on traditional textbooks, pomegranate has beneficial effects on diseases related to gastrointestinal, upper and lower respiratory, visual, and reproductive systems. Pomegranate and its preparations have also been prescribed for treating metabolic disorders, skin problems, and wounds, as well as for dental protection.

Pomegranate juice was used by the Greeks and Romans as a general cure-all. The fruit rind and tree bark were a remedy for diarrhea and stomach problems. The seeds and juice were considered a tonic for the heart.

Pomegranate has been employed in alternative medicine for the cure of a wide range of conditions, including the removal of tapeworms. Pomegranate fruit, peel, and root are commonly used in herbal medicine in many countries. Studies on ethnobotany indicate that fruits are mostly used to treat digestive problems, dry coughs, and urinary problems.

It is important to note that historical use was directed at pomegranate preparations as a whole — the peel, bark, juice, and root — and not at punicalin as an isolated compound. The identification of punicalin as a discrete phytochemical constituent is a product of modern analytical chemistry, and its role in mediating the traditional effects attributed to pomegranate is understood only in retrospect.

3. Key Constituents and Established Mechanisms of Action

3.1 Structural Relationship to Other Ellagitannins

Punicalin belongs to a family of ellagitannins that includes other minor tannins such as punicalagin and gallagic acid. Structurally, punicalin (C₃₄H₂₂O₂₂) may be understood as the gallagyl-glucose core of the larger punicalagin molecule (C₄₈H₂₈O₃₀), which additionally incorporates ellagic acid and hexahydroxydiphenic acid (HHDP) units. Ellagitannins are hydrolyzed rather than absorbed directly into the bloodstream. Punicalin is hydrolyzed in the intestines or stomach to create ellagic acid (EA), which intestinal bacteria then use to create urolithin A and B.

3.2 Antioxidant Mechanisms

Punicalagin and punicalin, isolated from the leaves of Terminalia catappa L., are used to treat dermatitis and hepatitis. Both compounds have strong antioxidative activity. Punicalin and punicalagin treatment increases HO-1 expression together with its upstream mediator nuclear factor-erythroid 2 p45-related factor 2 (Nrf2); specific inhibition of Nrf2 by brusatol dramatically blocked this HO-1 expression. Punicalin attenuates oxidative stress by decreasing the liver malondialdehyde level and increasing the activities of liver superoxide dismutase, glutathione peroxidase, and the expression of the liver nuclear factor E2-related factor (Nrf2) protein.

3.3 Anti-Inflammatory Mechanisms

Previous research has shown that punicalin/punicalagin inhibits LPS-induced mitogen-activated protein kinases (MAPKs) and NF-κB activation and thus suppresses overproduction of cytokines and inflammatory factors, including nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α).

In human peripheral blood mononuclear cells (PBMCs) from healthy donors, pomegranate peel extract and all individual ellagitannins (including punicalin) inhibited the levels of TNF-α, IL-6, and IL-8 dose-dependently, and their combinations acted synergistically.

Evidence indicates that punicalin inhibits activations of MAPK as well as NF-κB signaling pathways in human epidermal keratinocytes, and the two pathways are tightly linked to osteoclast formation.

3.4 Immunomodulatory Mechanisms

Inhibition of PTP1B by punicalagin/punicalin promoted an M2c-like macrophage polarization and enhanced anti-inflammatory cytokines expression, including IL-10 and M-CSF. M1-like macrophage marker genes, such as Tlr4, Irf1/2, Hmgb1, and Stat1, were down-regulated, while M2 marker genes, including Tmem171, Gpr35, Csf1, Il1rn, Cebpb, Fos, Vegfα, Slc11a1, and Bhlhe40, were up-regulated in punicalin/punicalagin-treated macrophages.

3.5 Anticancer Mechanisms

The mechanisms of actions of ellagitannins from pomegranate include selective induction of apoptosis of cancer cells, autophagy of cancer cells, decrease in oxidative stress, reduction of inflammation via down-regulation of pro-inflammatory factors and up-regulation of anti-inflammatory mediators, and maintenance of neuronal integrity. Punicalin and its metabolites have been shown to inhibit angiogenesis, proliferation, and induce apoptosis in osteosarcoma cancer cells, prostate cancer, colon cancer, and cervical cancer cell lines. Punicalin also suppresses various signaling pathways, including NF-κB, MAPK, Bcl-XL, and LKB1-AMPK-p27.

3.6 Metabolism and Bioavailability

All ellagitannins, including punicalin, have the same ability to be hydrolyzed in the small intestine to ellagic acid (EA). However, the bioavailability of ellagitannins and EA is very low, and compounds that are unable to be absorbed are then further metabolized. Gut bacteria metabolize punicalin and related ellagitannins into smaller, more absorbable compounds. The initial breakdown yields ellagic acid, which is then converted by specific gut bacteria into various urolithins. These urolithins, rather than the original ellagitannins, are more readily absorbed and are believed to be responsible for many health-promoting effects associated with consuming pomegranate and other ellagitannin-rich foods.

4. Scientific Evidence by Area of Use

Important caveat: The large majority of published research on punicalin involves in vitro (cell culture) or in vivo (animal model) studies. Dedicated human clinical trials specifically isolating punicalin as the intervention are absent from the published literature at this time. Much of the evidence cited below concerns pomegranate ellagitannin fractions in which punicalin is a recognized component, or comparative studies in which punicalin is tested alongside punicalagin and ellagic acid. Evidence strength is characterized accordingly throughout each subsection.

4.1 Antioxidant Activity

Punicalagin, punicalin, gallagic acid, and ellagic acid were found to account for the majority of the ellagitannins in pomegranate juices and homogenates. Research has shown that the antioxidant activity of pomegranate juices as measured by trolox equivalent antioxidant capacity (TEAC) and ascorbic acid equivalent antioxidant capacity (AEAC) methods was primarily attributable to the concentration of these hydrolyzable tannins.

In a comparative in vitro and in vivo study (Sun et al., 2017 in Journal of Integrative Agriculture), punicalin was among three major polyphenolic compounds from pomegranate peel — alongside ellagic acid and punicalagin — evaluated for antioxidant activities. This study assessed the in vitro and in vivo antioxidant activities of ellagic acid, punicalin, and punicalagin from pomegranate peel. All three compounds demonstrated strong free-radical scavenging activity; however, this study was conducted in animal models and does not constitute human clinical evidence.

Evidence strength: In vitro and animal data only. No specific human clinical trials on punicalin as isolated antioxidant have been published.

4.2 Anti-Inflammatory Activity

A key preclinical study by Lin et al. (1999, American Journal of Chinese Medicine) directly investigated punicalin's anti-inflammatory profile. Punicalagin and punicalin were isolated from the leaves of Terminalia catappa L., and the anti-inflammatory activity of both compounds was evaluated in carrageenan-induced hind paw edema in rats. Edema rates were increased by carrageenan administration and reduced by drug treatment. After 4 hours of carrageenan administration, the best effect group was the punicalagin (10 mg/kg) treated group (inhibition rate was 58.15%), and the second was the punicalagin (5 mg/kg)-treated group (inhibition rate was 39.15%). Even if the anti-inflammatory activity of punicalagin was the same as punicalin at the 5 mg/kg dose, the inhibition effect from larger doses of punicalagin was increased, but there was a decrease with a larger dose of punicalin. The data showed that both punicalagin and punicalin exert anti-inflammatory activity, but treatment with larger doses of punicalin may induce some cell damage.

An immunomodulatory study using human cells (PMC9695876) examined punicalin's cytokine-modulating effects directly in human peripheral blood mononuclear cells. Human peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated with phytohemagglutinin and treated with different concentrations of pomegranate peel extract or punicalagin (PG), punicalin (PN), and ellagic acid (EA), alone or in combinations. Cytotoxicity, cell proliferation, and cytokine production were determined. Non-cytotoxic concentrations of all compounds significantly inhibited cell proliferation. IC50 values (μg/mL) were: EA (7.56), PG (38.52), PEx (49.05), and PN (69.95). The extract and all ellagitannins inhibited the levels of TNF-α, IL-6, and IL-8 dose-dependently, and their combinations acted synergistically. This study used human cells but was conducted ex vivo (isolated cells in culture), not in human subjects.

Evidence strength: Preclinical (animal and ex vivo human cell) only. No randomized controlled trials in intact human subjects.

4.3 Hepatoprotective Activity

Several animal studies have specifically evaluated punicalin's liver-protective properties. The antihepatotoxic activity of punicalagin and punicalin on carbon tetrachloride (CCl4)-induced toxicity in the rat liver was evaluated. Levels of serum glutamate-oxalate-transaminase and glutamate-pyruvate-transaminase were increased by administration of CCl4 and reduced by drug treatment. Histological changes around the liver central vein and oxidation damage induced by CCl4 also benefited from drug treatment. The results show that both punicalagin and punicalin have anti-hepatotoxic activity, but that a larger dose of punicalin induced liver damage.

A related study on acetaminophen-induced toxicity (Lin et al., 2001, Phytotherapy Research, PMID 11351354) extended these hepatoprotective findings to another model of drug-induced hepatic injury in rats. Antioxidant and hepatoprotective effects of punicalagin and punicalin on acetaminophen-induced liver damage in rats were also documented.

In ICR mice, punicalagin ameliorated the CCl4-induced increase of the serum aspartate aminotransferase, alanine aminotransferase, the activity of liver lactate dehydrogenase, and the damage of histopathological structure. It attenuated oxidative stress by decreasing the liver malondialdehyde level and increasing the activities of liver superoxide dismutase, glutathione peroxidase, and the expression of the liver nuclear factor E2-related factor (Nrf2) protein.

Evidence strength: Animal models only. No human clinical data specific to punicalin hepatoprotection.

4.4 Antimicrobial Activity

Punicalin possesses documented antibacterial activity. Punicalin exerts many biological activities, including antibacterial activity. Punicalin and ellagic acid have been proven to have antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and some species of Clostridia. Punicalin has been confirmed to inhibit the growth of cariogenic bacteria at high concentrations. At subbactericidal concentrations, punicalin inhibits biofilm development and the production of acidic and extracellular polysaccharides by Streptococcus mutans, suggesting it has the potential to prevent tooth decay.

Punicalin's antiviral activity has also been documented in cell-based studies. The route of virus binding, infection entry, and spread during treatment with hydrolyzable tannins including punicalin was studied. Antiviral activity was found against viruses known to use cell surface glycosaminoglycans (GAGs) to enter the host cell. Punicalin has anti-hepatitis B virus and anti-HIV replication properties. These findings remain at the in vitro stage.

Antifungal activity has been noted in the context of the broader pomegranate tannin class. Punicalagin and punicalin have antifungal activity and act synergistically with fluconazole against candidiasis.

Evidence strength: In vitro studies only. No human clinical trials for any antimicrobial indication using isolated punicalin have been published.

4.5 Anticancer Activity

Pomegranate juice-derived ellagitannins (including punicalins and punicalagins) and the intestinal metabolites urolithins exhibited dose- and time-dependent decrease of cell proliferation on HT29 (colon cancer) cells, mediated by cell-cycle arrest and followed by the induction of cell death. Cell-cycle arrest induced by ellagitannins was mainly represented by a block in S phase, confirmed by the downregulation of cdk A and B1, necessary for cell progression to G2/M phase.

With respect to punicalin specifically: breast cancer cells are subjected to autophagic cell death induced by punicalin via initiation of the MAPK pathway and stopping the mTOR signaling chain. Different animal model studies have demonstrated the potential of punicalagin and related ellagitannins in blocking the MAPK/ERK and PI3K/AKT/mTOR signaling pathways in cancer.

In the domain of bone cancer and metastasis, a dedicated study examined punicalin's effect on osteoclastogenesis and breast cancer-associated bone loss. The efficacy of punicalin on receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast formation, F-actin ring formation, gene expression, bone resorption, NF-κB, and MAPK signaling pathways was assessed in vitro using molecular docking. The impact of punicalin on breast cancer-induced osteoclastogenesis, breast cancer cell proliferation, and apoptosis were also examined.

In a genotoxicity study, punicalin and ellagic acid did not show any mutagenic effect on Salmonella typhimurium; on the contrary, they showed protection against DNA damage and high antiproliferative activity. Punicalin and ellagic acid have been shown to have almost similar levels of antimutagenic properties against a number of mutagens and may be promising candidates for future anticancer drugs.

There is still a need for further clinical trials and studies to fully reveal punicalin's and punicalagin's potential as well as their safety.

Evidence strength: Preclinical (in vitro cell lines and animal models only). No human clinical data specific to punicalin as an isolated anticancer agent exist.

4.6 Lung-Protective Activity

An animal study directly investigated punicalin/punicalagin against LPS-induced acute lung injury (ALI). The study aimed to investigate the protective effect and mechanisms of punicalagin on lipopolysaccharide (LPS)-induced acute lung injury in mice. Forty-eight BALB/c male mice were used to establish ALI by intratracheal instillation of 2.4 mg/kg LPS; the mice were randomly divided into model and punicalagin (10, 20, 40 mg/kg) groups. The other 12 mice were intratracheal-instilled with the same volume of water as control. After 2 hours of receiving LPS, mice were administered drug through intraperitoneal injection. The result showed that punicalagin could reduce the lung index and wet/dry weight (W/D) ratio and improve lung histopathological injury. It decreased inflammation cells and regulated biomarkers in bronchoalveolar lavage fluid (BALF). Punicalagin dose-dependently reduced the phospho-protein levels of p65, IκBα, ERK1/2, JNK, and p38 in lung tissue, which demonstrated that the effect was related to the MAPK pathway. No toxicity was observed in the acute toxicity study. Punicalagin improves LPS-induced ALI mainly through its anti-inflammatory properties, which is associated with NF-κB and MAPK signaling pathways.

A separate study found that punicalin specifically attenuates LPS-induced acute lung injury by inhibiting inflammatory cytokine production and MAPK/NF-κB signaling in mice. Punicalin attenuates LPS-induced acute lung injury by inhibiting inflammatory cytokine production and MAPK/NF-κB signaling in mice.

Evidence strength: Animal (murine) model only. No human clinical trials.

4.7 Cardiovascular and Metabolic Activity

The biological functions of punicalagin in relation to glucose and lipid levels, paraoxonase 1 (PON1) activity, and inflammation were examined in vivo. Mice were fed a high-fat diet (HFD) for 12 weeks, and during the last 4 weeks, they received subcutaneous treatments via implanted minipumps that released physiological concentrations of punicalagin, quercetin, or atorvastatin daily into the serum. The HFD reduced serum PON1 activity, whereas punicalagin administration restored PON1 activity to the level of mice fed a normal diet. In addition, punicalagin significantly reduced glucose levels in HFD mice and improved HDL anti-inflammatory properties.

Mechanistically, beyond antioxidant activity, the mechanisms by which these polyphenols exert their beneficial properties appear to involve their interaction with serum proteins that mediate HDL function and lipid-glucose state in the circulation.

Evidence strength: Animal model only. Clinical cardiovascular evidence pertains to pomegranate juice as a whole product, not to isolated punicalin.

4.8 Anti-COVID-19 / Antiviral Potential

Punicalagin has been identified as an allosteric inhibitor of the SARS-CoV-2 3CLpro main protease, which cleaves polyproteins to produce non-structural proteins. It also disrupts the association between the virus spike glycoprotein and the cellular receptor ACE2, potentially inhibiting virus entry into host cells. Punicalagin-targeting proteins play various roles in the virus life cycle; thus, the potent anti-SARS-CoV-2 efficacy in cells could be ascribed to a multi-targeting effect. These findings were obtained in in vitro and computational (in silico) studies; no clinical human data exist for either punicalin or punicalagin against SARS-CoV-2.

Evidence strength: In vitro and computational (in silico) data only.

5. Body Systems and Health Areas Associated with Punicalin

• Gastrointestinal system: Pomegranate and its peel, which contain punicalin, were widely used in folk medicine for the treatment of respiratory diseases, diarrhea, parasite infection, hemorrhage, and ulcers.
• Hepatic (liver) system: Punicalin has demonstrated hepatoprotective effects in rodent models of CCl4- and acetaminophen-induced liver injury, operating through antioxidant and autophagy mechanisms.
• Immune and inflammatory system: Punicalin modulates NF-κB, MAPK, and Nrf2/HO-1 pathways, reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and shifts macrophage polarization toward anti-inflammatory phenotypes.
• Respiratory system: Animal models support punicalin's attenuation of acute lung injury via NF-κB/MAPK suppression.
• Skeletal/bone system: Punicalin inhibits RANKL-mediated osteoclastogenesis and has been studied in models of breast cancer-associated osteolysis.
• Cardiovascular and metabolic system: Related ellagitannins have been shown in animal models to restore paraoxonase-1 activity, reduce blood glucose, and improve HDL anti-inflammatory properties.
• Oncology (preclinical): Punicalagin/punicalin have lipid-lowering, anti-inflammatory, anticancer, antidiabetic, antioxidant, antimicrobial, neuroprotective, nephroprotective, hepatoprotective, bone-protecting, skin-protecting, lung-protecting, wound-healing, and hematological properties in preclinical evidence.
• Oral and dental health: At sub-bactericidal concentrations, punicalin inhibits biofilm development and the production of acidic and extracellular polysaccharides by Streptococcus mutans, suggesting potential to prevent tooth decay.

6. Dosage Forms and Dosages Reported in Studies

Punicalin is not currently approved or standardized as a pharmaceutical agent, and no human clinical dosing recommendations exist. The following dosages are those specifically reported in preclinical research:

• In the carrageenan-induced rat paw edema model, the best anti-inflammatory effect group was the punicalagin (10 mg/kg) treated group, with an inhibition rate of 58.15%. Punicalin tested at the same doses (5 mg/kg and 10 mg/kg) showed reduced efficacy at higher doses, and cell damage was observed at larger doses of punicalin.
• In the LPS-induced acute lung injury mouse model, punicalagin was administered at doses of 10, 20, and 40 mg/kg via intraperitoneal injection.
• In an ovariectomized (OVX) mouse model of bone loss, punicalin was administered at 5 mg/kg/day intraperitoneally.
• In the human PBMC immunomodulatory in vitro study, punicalin was investigated at double increasing concentrations ranging from 10–80 μg/mL.
• Punicalin has been reported to be toxic to cattle. For punicalagin, a 6% punicalagin-containing diet for 37 days in Sprague-Dawley rats was found not to produce significant systemic toxicity.

No oral human dosing regimen for isolated punicalin has been established in published clinical research. Pomegranate juice, which contains punicalin as part of a complex ellagitannin mixture, has been studied clinically in cardiovascular and prostate contexts, but the contribution of punicalin specifically to those effects cannot be isolated from the available data.

7. Safety Considerations

7.1 Animal Toxicology

The water-soluble ellagitannin punicalagin has been reported to be toxic to cattle. Taking into account that this antioxidant polyphenol is very abundant in pomegranate juice (≥2 g/L), a study evaluated the possible toxic effect of punicalagin in Sprague-Dawley rats upon repeated oral administration of a 6% punicalagin-containing diet for 37 days. Feedstuff intake, food utility index, and growth rate were lower in treated rats during the first 15 days without significant adverse effects. No significant differences were found in treated rats in any blood parameter analyzed (including the antioxidant enzymes glutathione peroxidase and superoxide dismutase) with the exception of urea and triglycerides, which remained at low values throughout the experiment. Histopathological analysis of liver and kidney corroborated the absence of toxicity. The results, together with the large safety margin considered, indicate the lack of toxic effect of punicalagin in rats during the 37-day period investigated.

7.2 Dose-Dependent Hepatotoxicity Warning for Punicalin Specifically

A critical finding specific to punicalin — as distinguished from punicalagin — is the following: the results show that both punicalagin and punicalin have anti-hepatotoxic activity, but that the larger dose of punicalin induced liver damage. Thus, even if tannins have strong antioxidant activity at very small doses, treatment with a larger dose will induce cell damage. Harmful effects were observed with 25 μg/g of body weight of punicalin in preclinical studies. This biphasic toxicity profile — hepatoprotective at low doses, potentially hepatotoxic at high doses — is an important safety consideration that distinguishes punicalin from its structural analog punicalagin, which was not toxic in the 37-day rat study.

7.3 Cytotoxicity Considerations

Non-cytotoxic concentrations of punicalin significantly inhibited cell proliferation. The IC50 value for punicalin (PN) in terms of cell proliferation inhibition was 69.95 μg/mL — higher (less potent in cytotoxicity) than ellagic acid (IC50 7.56 μg/mL) and punicalagin (IC50 38.52 μg/mL), indicating relatively greater safety margin for punicalin at lower concentrations.

7.4 Bioavailability and Metabolic Interactions

The bioavailability of ellagitannins such as punicalin is low due to their large molecular size and limited direct absorption. Their health effects are largely mediated by their metabolites, urolithins, which are produced by gut bacteria and are better absorbed. This means that individual variation in gut microbiome composition could substantially affect punicalin's efficacy and metabolite profile, making its effects variable across individuals. No specific drug-interaction studies for punicalin as an isolated compound have been published in the peer-reviewed literature reviewed.

7.5 Important Note on Retracted Literature

At least one published study on punicalin's effects in LPS-induced acute lung injury (Journal of Healthcare Engineering, 2022) was subsequently retracted (the original article was retracted; punicalin's attenuation of LPS-induced acute lung injury by inhibiting inflammatory cytokine production and MAPK/NF-κB signaling in mice was the subject of that retracted report). A separate 2023 publication in Heliyon (PMID 37101633) addressed the same subject. Readers should verify the current status of any cited primary literature before relying on specific numerical findings.

References

• Lin CC, Hsu YF, Lin TC, Hsu HY. Antioxidant and hepatoprotective activity of punicalagin and punicalin on carbon tetrachloride-induced liver damage in rats. PubMed PMID: 9720629
• Lin CC, Hsu YF, Lin TC. Effects of punicalagin and punicalin on carrageenan-induced inflammation in rats. Am J Chin Med. 1999;27(3-4):371-6. PubMed PMID: 10592846
• Cerda B et al. Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem. 2003. PubMed PMID: 12744688
• Immunomodulatory Activity of Punicalagin, Punicalin, and Ellagic Acid Differs from the Effect of Pomegranate Peel Extract. PMC9695876
• Punicalagin Induces Nrf2/HO-1 Expression via Upregulation of PI3K/AKT Pathway and Inhibits LPS-Induced Oxidative Stress in RAW264.7 Macrophages. PMC4417599
• Punicalagin, a PTP1B inhibitor, induces M2c phenotype polarization via up-regulation of HO-1 in murine macrophages. PubMed PMID: 28690198
• Lung-protective effect of Punicalagin on LPS-induced acute lung injury in mice. PMC8787312
• Punicalagin Reversed the Hepatic Injury of Tetrachloromethane by Antioxidation and Enhancement of Autophagy. PMC6918856
• Physiological and Immune Functions of Punicalagin. PMC8308219
• Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. PMC4477247
• Exploring Punicalagin Potential Against Cancers: A Comprehensive Review. PMC11866048
• Bioactive potential of punicalagin: A comprehensive review. ScienceDirect, October 2024
• Advances towards the analysis, metabolism and health benefits of punicalagin, one of the largest ellagitannin from plants. ScienceDirect, 2022
• Pomegranate Punicalagin: A Comprehensive Review of Various In Vitro and In Vivo Biological Studies. ACS Food Science & Technology
• Identification of Punicalagin as a Key Bioactive Compound Responsible for the Antimicrobial Properties of Punica granatum L. Peel Extract. PMC12291446
• Antibacterial and antiviral properties of punicalagin (Review). PMC12415540
• Antimicrobial Activity of Punicalagin Against Staphylococcus aureus and Its Effect on Biofilm Formation. PubMed PMID: 28128637
• Punicalagin suppresses methicillin resistance of Staphylococcus aureus to oxacillin. ScienceDirect
• Antibacterial and Antifungal Activities of Punica granatum Peel Extracts Against Oral Pathogens. PMC3184731
• An in vitro antiviral evaluation of punicalagin toward influenza A virus. PMC11179181
• Punicalagin Decreases Serum Glucose Levels and Increases PON1 Activity and HDL Anti-Inflammatory Values in Balb/c Mice Fed a High-Fat Diet. PMC6091419
• Punicalagin Protects against Diabetic Liver Injury by Upregulating Mitophagy and Antioxidant Enzyme Activities. PMC9319303
• Review of Pharmacological and Medicinal Uses of Punica granatum. PMC11563771
• Pomegranate: A review of the heavenly healer's past, present, and future. PMC10598818
• A unique understanding of traditional medicine of pomegranate, Punica granatum L. and its current research status. ScienceDirect
• Update on the Potential of Punica granatum L. Traditional Uses and Pharmacological Uses: A Review. Wiley Online Library, 2024
• Pomegranate seeds: a comprehensive review of traditional uses, chemical composition, and pharmacological properties. Frontiers in Pharmacology, 2024
• Determination of Ellagic Acid, Punicalagin, and Castalagin from Terminalia ferdinandiana by a Validated UHPLC-PDA-MS/MS Methodology. Springer Nature Link
• Pomegranate as a Functional Food and Nutraceutical Source. USDA ARS
• Ethnobotany of Fruit Trees. U.S. National Park Service
• Effects of Punicalagin and Punicalin on Carrageenan-Induced Inflammation in Rats. ResearchGate
• Antifungal Activity and DNA Topoisomerase Inhibition of Hydrolysable Tannins from Punica granatum L. PMC8073005